Testing new outcomes in primary Sjögren’s syndrome
Treatments studied
Part of Eyes & vision, Mouth & dental clinical trials.
This Phase 2 study tests how to measure changes in primary Sjögren’s syndrome symptoms and body activity. It may help researchers confirm which outcomes best reflect improvement and how different patient types respond to treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older and able to sign written consent.
- You must have primary Sjögren’s syndrome diagnosed by accepted criteria (ACR/EULAR 2016 or AECG 2002).
- Your symptom level must be high (ESSPRI 5 or more) and your overall body inflammation level must be either lower (ESSDAI < 5) or moderate/high (ESSDAI 5 or more), depending on which group you fit.
- If you can become pregnant, you must have a negative pregnancy test and use highly effective birth control during the study and for 2 years after stopping.
- You must not be in another medicine trial at the same time.
- You must not have certain eye, liver/kidney, infection, blood count, heart rhythm, or cancer conditions that could make the study unsafe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows people who have signs that might mean Sjögren’s syndrome and looks at how well a standardized work-up identifies the condition. It may help doctors confirm the diagnosis earlier and more consistently.
This study tests a new pill called upadacitinib (a JAK inhibitor) for people with active Sjögren's syndrome. It may help reduce dryness, fatigue, and joint pain by calming the immune system.
This study tests a new drug called CM336 for people with primary Sjögren's syndrome (an autoimmune disease affecting salivary and tear glands). The drug is designed to help reduce disease activity in patients who haven't responded well to previous treatments.
This study tests an investigational drug called ICP-488 for people with primary Sjögren's syndrome (the main form, not caused by other conditions). The goal is to see if the drug can help control symptoms better than a placebo. Participants must have active disease and stable treatment.
This study tests an investigational drug called RSLV-132 in women with Sjögren's disease to see if it can reduce symptoms like fatigue and dryness. You may join if you've been diagnosed in the last 30 years and have persistent symptoms.
This trial studies whether iguratimod improves symptoms in people with primary Sjögren’s syndrome, and checks how safe it is. It focuses on people with confirmed disease markers (anti-SSA/Ro-60) and ongoing dry eyes and dry mouth.
Hear when a new Primary Sjögren's Syndrome (pSS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.